Skip to content

Author

Seyit Uyar

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Aug 2026

Disease-modifying anti-diabetic drugs (DMADDs): bridging the SIMPLE approach to disease interception

The traditional glucose-centric paradigm of type 2 diabetes management is being superseded by growing evidence that certain agents, sodium-glucose cotransporter-2 inhibitors (SGLT2i), glucagon-like peptide−1 receptor agonists (GLP-1RA), and pioglitazone, confer cardiovascular, renal, and hepatic benefits that extend we...

Nizameddin Koca, Seyit Uyar, Y. Şahintürk et al. · 0 citations
Open access Aug 2026

Hepatic fibrosis severity assessed by FIB-4 index is independently associated with reduced kidney function in patients with metabolic dysfunction-associated steatotic liver disease: a nationwide multicenter study from Türkiye.

The role of FIB-4 as a simple, cost-effective tool for integrated cardio-hepato-renal risk stratification is supported, and impaired kidney function in patients with MASLD beyond established cardiometabolic risk factors is independently associated with impaired kidney function in patients with MASLD.

H. Sumbul, A. Kırık, S. Yaylacı et al. · 1 citation

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.